Opexa (Bilastine)

Bilastine, the active ingredient in Opexa, is an antihistamine presented as an oral tablet for oral use. It acts as a selective peripheral H1‑receptor antagonist and is indicated for the relief of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents.

GNH USA supplies Opexa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The company adheres to stringent quality standards and offers comprehensive logistics support, including temperature‑controlled shipping where required.

Bilastine is an antihistamine that targets histamine‑mediated allergic responses. - Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge. - Seasonal allergic rhinoconjunctivitis: alleviates eye irritation and nasal symptoms associated with seasonal allergens. - Chronic idiopathic urticaria: diminishes wheal formation and itching in patients with persistent hives.

Bilastine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Dry mouth: sensation of oral dryness that may improve with hydration. - Fatigue: transient tiredness, usually not dose‑limiting. - Nausea: mild gastrointestinal upset. - Dizziness: occasional light‑headed feeling. - Mild insomnia: occasional difficulty falling asleep.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare severe skin reactions. - Cardiac arrhythmia: extremely rare, monitor patients with pre‑existing heart disease. - Hepatic injury: rare elevation of liver enzymes. - Severe hypersensitivity: rash, swelling, or bronchospasm. - Hematologic abnormalities: rare cases of neutropenia or thrombocytopenia.

Bilastine should be used with awareness of specific safety considerations. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion in milk; weigh benefits against possible infant exposure. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors without medical guidance. - Driving and machinery: may cause mild drowsiness; exercise caution when operating vehicles. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Bilastine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ketoconazole (strong CYP3A4 inhibitor): can raise bilastine plasma levels. - Erythromycin (CYP3A4 inhibitor): may increase exposure. - Ritonavir (potent CYP3A4 inhibitor): risk of heightened adverse effects. - Antacids containing aluminum or magnesium: reduce oral absorption of bilastine.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance sedation. - Other antihistamines: additive antihistaminic effect may increase drowsiness. - Grapefruit juice: potential modest increase in bilastine levels. - Certain antidepressants (e.g., fluoxetine): monitor for enhanced side effects.